Duvelisib was the next PI3K inhibitor authorised from the FDA, also depending on a stage III randomized trial.130 The efficacy and basic safety profile with the drug appear comparable with those of idelalisib, if not slightly useful. Regarding alternate BTK inhibitors, there are lots of solutions in